News

Technology News

Cellerant Therapeutics Nets Venture Capital Debt

Friday, April 15, 2016 5:01:00 AM PDT | VentureDeal


San Carlos, California  --  Biotechnology company Cellerant Therapeutics has secured $2 million in debt venture capital, according to an SEC regulatory filing.

Cellerant develops products for the "regulation of the amount of the hematopoietic system."

Its lead product is a myeloid progenitor cell therapy for patients with acute myeloid leukemia.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

A total of seven investors participated in the offering.

CEO Ram Mandalam has been with the company since 2005.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1